Japan Active Pharmaceutical Ingredient Cdmo Market Size & Outlook
Related Markets
Japan active pharmaceutical ingredient cdmo market highlights
- The Japan active pharmaceutical ingredient cdmo market generated a revenue of USD 5,252.3 million in 2024 and is expected to reach USD 11,746.1 million by 2033.
- The Japan market is expected to grow at a CAGR of 9.4% from 2025 to 2033.
- In terms of segment, traditional active pharmaceutical ingredient (traditional api) was the largest revenue generating product in 2024.
- Antibody Drug Conjugate (ADC) is the most lucrative product segment registering the fastest growth during the forecast period.
Active pharmaceutical ingredient cdmo market data book summary
| Market revenue in 2024 | USD 5,252.3 million |
| Market revenue in 2033 | USD 11,746.1 million |
| Growth rate | 9.4% (CAGR from 2025 to 2033) |
| Largest segment | Traditional active pharmaceutical ingredient (traditional api) |
| Fastest growing segment | Antibody Drug Conjugate (ADC) |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API), Antibody Drug Conjugate (ADC) |
| Key market players worldwide | Recipharm, Thermo Fisher Scientific Inc, Samsung BioLogics, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim, Cambrex, CordenPharma |
Other key industry trends
- In terms of revenue, Japan accounted for 4.9% of the global active pharmaceutical ingredient cdmo market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China active pharmaceutical ingredient cdmo market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 20,807.4 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Active Pharmaceutical Ingredient CDMO Market Scope
Active Pharmaceutical Ingredient CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Cambrex | View profile | 1001-5000 | East Rutherford, New Jersey, United States, North America | http://www.cambrex.com |
| CordenPharma | View profile | 5001-10000 | Plankstadt, Baden-Wurttemberg, Germany, Europe | http://cordenpharma.com |
| Piramal Pharma Solutions | View profile | 1001-5000 | Riverview, Michigan, United States, North America | http://www.piramalpharmasolutions.com/ |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | https://www.samsungbiologics.com/ |
| Recipharm | View profile | 1001-5000 | Jordbro, Stockholms Lan, Sweden, Europe | http://www.recipharm.com |
| Siegfried Holding AG | View profile | 4180 | Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 | https://www.siegfried.ch |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | https://www.boehringer-ingelheim.com/ |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
Japan active pharmaceutical ingredient cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to active pharmaceutical ingredient cdmo market will help companies and investors design strategic landscapes.
Traditional active pharmaceutical ingredient (traditional api) was the largest segment with a revenue share of 48.58% in 2024. Horizon Databook has segmented the Japan active pharmaceutical ingredient cdmo market based on traditional active pharmaceutical ingredient (traditional api), highly potent active pharmaceutical ingredient (hp-api), antibody drug conjugate (adc) covering the revenue growth of each sub-segment from 2021 to 2033.
Some of the key drivers of Japan’s active pharmaceutical ingredients CDMO market are its growing pharmaceutical industry, rapid technological advancements, and high healthcare expenditure. Japan is expected to show lucrative growth rate of 9.6% during the forecast period.
Presence of a stringent regulatory framework and high standards for API manufacturing are increasing the overall costs, thus, promoting the need to maintain standards while reducing healthcare expenditure.
Furthermore, a large number of CDMO collaborations, expansions, mergers & acquisitions, and other strategic initiatives undertaken by market players operating in the country are anticipated to boost the market.
Reasons to subscribe to Japan active pharmaceutical ingredient cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan active pharmaceutical ingredient cdmo market databook
-
Our clientele includes a mix of active pharmaceutical ingredient cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan active pharmaceutical ingredient cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Japan active pharmaceutical ingredient cdmo market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Japan Product - Active Pharmaceutical Ingredient Cdmo Market size, 2024 - 2033 (US$M)
Japan Active Pharmaceutical Ingredient CDMO Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
